LIXTE Biotechnology Reports Promising Interim Results for LB-100 Combination Therapy in Ovarian Cancer Trial

LIXTE Biotechnology Holdings announced preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference. Interim data from 20 evaluable patients showed a 40% disease control rate and encouraging survival trends with an acceptable safety profile, supporting continued enrollment of an expanded cohort as the company investigates the combination's potential to enhance immunotherapy response in ovarian clear cell carcinoma.

The company's lead compound LB-100 represents a first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. This approach is part of a pioneering effort in an entirely new field of cancer biology called activation lethality, which is advancing a new treatment paradigm for difficult-to-treat cancers.

LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. Additional information about the company's research and development can be found at https://www.lixte.com. The interim results presented at the gynecologic oncology conference suggest that combining LB-100 with immunotherapy agents like dostarlimab may help overcome resistance mechanisms that have limited the effectiveness of immunotherapies in certain cancer types.

Through its wholly owned subsidiary Liora Technologies Europe Ltd., the company is also developing electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora's proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. More details about this technology are available at https://www.lioratechnologies.com.

The clinical trial results matter because ovarian clear cell carcinoma represents a particularly aggressive subtype of ovarian cancer that has shown limited response to conventional therapies. The 40% disease control rate observed in this interim analysis suggests that LB-100 may help sensitize these tumors to immunotherapy approaches, potentially offering new treatment options for patients with this challenging cancer type. The acceptable safety profile reported in the preliminary data indicates that the combination therapy may be manageable for patients, which is crucial for advancing through clinical development stages.